Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
| Revenue (TTM) | $4.18B |
| Gross Profit (TTM) | $1.43B |
| EBITDA | $637.30M |
| Operating Margin | 3.47% |
| Return on Equity | -52.20% |
| Return on Assets | 2.09% |
| Revenue/Share (TTM) | $30.11 |
| Book Value | $18.09 |
| Price-to-Book | 0.61 |
| Price-to-Sales (TTM) | 0.35 |
| EV/Revenue | 1.151 |
| EV/EBITDA | 8.41 |
| Quarterly Earnings Growth (YoY) | -63.60% |
| Quarterly Revenue Growth (YoY) | -7.20% |
| Shares Outstanding | $138.37M |
| Float | $137.65M |
| % Insiders | 0.39% |
| % Institutions | 116.73% |
Volatility is currently expanding
DUBLIN, June 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo"), a leading provider of consumer health products, today announced that its Board of Directors has appointed Salman Amin and Omer Gajial as independent directors, effective June 30, 2026. "We are pleased to welcome Salman and Omer to Perrigo's Board," said Orlando D.
Albert A. Manzone Appointed Interim President and CEO Patrick Lockwood-Taylor Resigns as President and CEO and as a Member of the Board DUBLIN, June 8, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that its Board of Directors has appointed Albert A. Manzone, a member of the Company's Board, as Interim President and Chief Executive Officer, effective immediately.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
DUBLIN, May 26, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on Tuesday, June 9th at 10:30 AM EDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.
Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript
Perrigo (PRGO) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.6 per share a year ago.
Advances key Three-S plan pillar, streamlining portfolio Upfront net proceeds of approximately €306 million will enable debt reduction DUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next three years.
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
